The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.
Phase of Trial: Phase II
Latest Information Update: 19 May 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- 03 Sep 2015 New trial record